John MaherCSO, Leucid Bio at Clinical Senior Lecturer in Immunology, Kings College London
Dr John Maher is a clinical immunologist who leads the "CAR Mechanics" research group within King's College London. He played a key role in the early development of second generation (CD28) CAR technology while a visiting fellow at Memorial Sloan Kettering Cancer Center, an approach that has achieved clinical impact in haematological malignancies. His research group is focused on the development of adoptive immunotherapy using CAR engineered and gamma delta T-cells, with a primary emphasis on solid tumour types. He is also the scientific founder and chief scientific officer of a spin-out company named Leucid Bio. In addition, he is a consultant immunologist within King's Health Partners and Eastbourne Hospital.